Established in 1994, Current Oncology is a peer-reviewed, Canadian based and Internationally distributed journal. Published bi-monthly plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is published by Multimed Inc.
Current Oncology is indexed/covered in PubMed, EMBASE (Excerpta Medica Database), Scopus, Journal Selector, CrossRef, Index Copernicus, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC), the U.S. National Library of Medicine's digital archive of biomedical and life sciences journal literature. It is also available in the databases of 100 libraries worldwide, and is a participant of the HINARI program.
The information provided on the Current Oncology website is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
GIOTRIF® (afatinib) approved by Health Canada for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation
On November 6, 2013, Health Canada approved GIOTRIF® (afatinib) a targeted, oral once-daily tyrosine kinase inhibitor and the first irreversible ErbB Family Blocker approved for the treatment of EGFR mutation positive tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) tablets.
In clinical trials, GIOTRIF® has been shown to offer patients with EGFR mutation positive NSCLC a significant delay in tumour progression,[i] coupled with improvements in their lung cancer related symptoms versus standard chemotherapy.[i]
Dr. Vera Hirsh, GIOTRIF® clinical trial investigator and medical oncologist at Royal Victoria Hospital in Montreal says, “The approval of GIOTRIF® is an exciting advancement because it works differently than other drugs in its class, by irreversibly blocking multiple EGFR pathways involved in tumour growth.”
GIOTRIF®’s unique mode of action enables it to block EGFR (ErbB1) as well as the other relevant members of the ErbB Family. The covalent and, therefore, irreversible binding of GIOTRIF® is unlike other compounds currently on the market which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade.[i],[ii]
Discovered and developed by Boehringer Ingelheim, GIOTRIF® is the first Health Canada-approved oncology product from the company.
[i] Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
[ii] Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award!
Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award! Dr. Gold will be awarded the Wilder-Penfield Prize for his work in the ground-breaking discovery of the carcinoembryonic antigen (CEA).
The CEA was discovered in 1965 by Dr. Gold and his colleague, Samuel Freedman. This discovery revolutionized cancer research and is now the most frequently used blood test in modern oncology. The discovery of the CEA also launched the field of oncodevelopmental biology.
Thank you for your important contribution to oncology, Dr. Gold!
Meeting/Conference: 18th International Conference on Cancer Nursing (ICCN)
|The International Society of Nurses in Cancer Care (ISNCC) invites you to the 18th International Conference of Cancer Nursing (ICCN), to be held at the Hilton Panama, Panama City, Panama, from September 7 -11, 2014. The theme for this conference is ‘Strengthening Leadership, Unity and Compassion in Cancer Care. We are anticipating approximately 500 cancer nursing professionals across the globe to attend this conference.
Call for Abstracts
ISNCC is now accepting abstract submissions for oral or poster presentations addressing the conference theme. Abstracts may be submitted in either English or Spanish. Abstracts submitted in Spanish will be evaluated for Spanish language only concurrent sessions and not for English language concurrent sessions or for poster sessions. A total of 12 Spanish language abstracts will be accepted. Abstracts will be selected based on the following categories:
Click here to download the official call for abstracts announcement.
Abstract Submission Deadline: January 16, 2013 at 3:00 AM ET
For more information on how to submit an abstract, please visit http://www.isncc.org/?page=18ICCN_Abstracts
Online rregistration is now open. ISNCC is now offering a discounted registration rate for ISNCC individual members. Click here to learn more.
Early Registration Deadline: May 15, 2014
Visit http://www.isncc.org/?page=18th_ICCN for conference update.
Vol 21, No 2 (2014)
Table of Contents
|Palliative sedation— still a complex clinical issue!|
|A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers|
|S.A. Narod, N. Tung, J. Lubinski, T. Huzarski, M. Robson, H.T. Lynch, S.L. Neuhausen, P. Ghadirian, C. Kim–Sing, P. Sun, W.D. Foulkes, The Hereditary Breast Cancer Clinical Study Group||64-68|
Cancer Rehabilitation and Survivorship
|Patient perceptions of a comprehensive cancer navigation service|
|W. Hryniuk, R. Simpson, A. McGowan, P. Carter||69-76|
|Prospective evaluation of unmet needs of rural and aboriginal cancer survivors in Northern British Columbia|
|R.A. Olson, F. Howard, K. Turnbull, D. Munroe, C. Zirul, R. Manji, P. Tobin, A. Ward||e179-e185|
|Rasch analysis of the Edmonton Symptom Assessment System and research implications|
|O. Cheifetz, T.L. Packham, J.C. MacDermid||e186-e194|
|Surgical process improvement tools: defining quality gaps and priority areas in gastrointestinal cancer surgery|
|A.C. Wei, K.S. Devitt, M. Wiebe, O.F. Bathe, R.S. McLeod, D.R. Urbach||e195-e202|
|Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience|
|R.D. Peixoto, W.Y. Cheung, H.J. Lim||77-83|
|Patients’ perceptions of gene expression profiling in breast cancer treatment decisions|
|Y. Bombard, L. Rozmovits, M.E. Trudeau, N.B. Leighl, K. Deal, D.A. Marshall||e203=e211|
|Potential drug interactions in patients with a history of cancer|
|L. Chen, W.Y. Cheung||e212-e220|
|Toward successful migration to computerized physician order entry for chemotherapy|
|J. Jeon, S. Taneva, V. Kukreti, P. Trbovich, A.C. Easty, P.G. Rossos, J.A. Cafazzo||e221-e228|
|The use of granulocyte colony– stimulating factors in a Canadian outpatient setting|
|S. Fine, M. Koo, T. Gill, M. Marin, M. Poulin-Costello, R. Baron, N. Mittmann||e229-e240|
|Can oncologists predict survival for patients with progressive disease after standard chemotherapies?|
|T.K. Taniyama, K. Hashimoto, N. Kastumata, A. Hirakawa, K. Yonemori, M. Yunokawa, C. Shimizu, K. Tamura, M. Ando, Y. Fujiwara||84-90|
|Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia|
|D. Sanford, R. Kyle, A. Lazo–Langner, I. Chin–Yee, K. Howson–Jan, C. Hsia||e241-e249|
|Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87|
|M.T. Niazi, G. Mok, M. Heravi, L. Lee, T. Vuong, R. Aloyz, L. Panasci, T. Muanza||91-96|
|Publication rates of abstracts presented at the 2007 and 2010 Canadian Association of Radiation Oncology meetings|
|A. Meissner, G. Delouya, D. Marcovitch, D. Donath, D. Taussky||e250-e254|
|The road ahead for cervical cancer prevention and control|
|J.E. Tota, A.V. Ramana–Kumar, Z. El-Khatib, E.L. Franco||e255-e264|
|Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome–positive or BCR-ABL–positive acute lymphoblastic leukemia: a Canadian consensus|
|S. Couban, L. Savoie, Y. Abou Mourad, B. Leber, M. Minden, R. Turner, V. Palada, N. Shehata, A. Christofides, S. Lachance||e265-e309|
|Extracorporeal photopheresis in the management of graft-versus-host disease|
|C. Bredeson, R.B. Rumble, N.P. Varela, J. Kuruvilla, C.T. Kouroukis, Stem Cell Transplant Steering Committee||e310-e325|
Cancer System Indicator Snapshots
|Geographic disparities in surgery for breast and rectal cancer in Canada|
|T. Forte, G. Porter, R. Rahal, K. DeCaria, J. Niu, H. Bryant, the System Performance Steering Committee and Technical Working Group||97-99|
|Practice and documentation of palliative sedation: a quality improvement initiative|
|M. McKinnon, C. Azevedo, S.H. Bush, P. Lawlor, J. Pereira||100-103|
|Predictors of recurrence after radiotherapy for non-melanoma skin cancer|
|L. Khan, D. Breen, L. Zhang, J. Balogh, G. Czarnota, J. Lee, M.N. Tsao, E.A. Barnes||e326-e329|
|Screening for distress in patients with cancer: methodologic considerations|
|A. Feldstain, M. Bélanger, C. Tomei, S. Lebel||e330-e333|
|Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation|
|N. Kiss, J. Seymour, M. Prince, G. Dutu||e334-e339|
|Metabolic syndrome–related hepatocellular carcinoma treated by volumetric modulated arc therapy|
|J. Klein, L.A. Dawson, T.H. Tran, O. Adeyi, T. Purdie, M. Sherman, A. Brade||e340-e344|
|FDG-PET in two cases of neurofibromatosis type 1 and atypical malignancies|
|P. de Blank, K. Cole, L. Kersun, A. Green, J.J. Wilkes, J. Belasco, R. Bagatell, L.C. Bailey, M.J. Fisher||e345-e348|
|Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy|
|P. Wong, K. Han||e349-e353|
|Localized synchronous squamous cell carcinomas of the esophagus and hypopharynx treated with definitive concurrent chemoradiotherapy with a unified radiotherapy plan|
|J.B. Wallach, M.M. Rosenstein, S. Kalnicki||e354-e357|
|Proffered papers and posters submitted to the Fifth International Symposium on Hereditary Breast and Ovarian Cancer, BRCA: Twenty Years of Advances|
|Hereditary Breast and Ovarian Cancer Foundation, Program in Cancer Genetics, McGill University||e358-e391|
Cancer Narratives: Words Beyond Disease
|Corrigendum: A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events|
Copyright © 2014 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)